ACAD
41.67
-0.21
-0.50%
AEMD
7
+0.49
+7.53%
APRI
1.68
-0.03
-1.75%
ARNA
4.47
-0.17
-3.66%
ATEC
1.38
0.00
0.00%
CNAT
5.24
+0.09
+1.75%
CRXM
0.36
0.00
0.00%
CYTX
0.551
-0.006
-1.1490%
DXCM
79.77
-0.21
-0.26%
GNMK
8.75
-0.31
-3.42%
HALO
22.5
-0.08
-0.35%
ILMN
220.71
+2.35
+1.08%
INNV
0.12
0.00
0.00%
INO
8.145
-0.015
-0.184%
ISCO
0.047
+0.003
+7.8886%
ISIS
57.16
-0.39
-0.68%
LGND
97.09
-3.81
-3.78%
LPTN
0.28
+0.004
+1.3406%
MBVX
2.52
+0.2
+8.62%
MEIP
1.7
-0.01
-0.58%
MNOV
3.93
-0.02
-0.51%
MRTX
31.69
+0.22
+0.70%
MSTX
0.49
0.00
0.00%
NBIX
47.66
-0.1
-0.21%
NUVA
47.52
+0.14
+0.30%
ONCS
6.6
+0.27
+4.27%
ONVO
3.71
-0.06
-1.59%
OREX
4.93
-0.02
-0.40%
OTIC
22.61
-0.38
-1.65%
QDEL
22.97
+0.02
+0.09%
RCPT
196.27
+6.22
+3.27%
RGLS
10.54
-0.42
-3.83%
RMD
55.3
-1.07
-1.90%
SCIE
0.015
-0.003
-14.773%
SPHS
0.783
-0.002
-0.2676%
SRNE
17.15
-0.47
-2.67%
TROV
9.72
-0.43
-4.24%
VICL
0.685
-0.015
-2.143%
ZGNX
13.96
+0.52
+3.87%
ACAD
41.67
-0.21
-0.50%
AEMD
7
+0.49
+7.53%
APRI
1.68
-0.03
-1.75%
ARNA
4.47
-0.17
-3.66%
ATEC
1.38
0.00
0.00%
CNAT
5.24
+0.09
+1.75%
CRXM
0.36
0.00
0.00%
CYTX
0.551
-0.006
-1.1490%
DXCM
79.77
-0.21
-0.26%
GNMK
8.75
-0.31
-3.42%
HALO
22.5
-0.08
-0.35%
ILMN
220.71
+2.35
+1.08%
INNV
0.12
0.00
0.00%
INO
8.145
-0.015
-0.184%
ISCO
0.047
+0.003
+7.8886%
ISIS
57.16
-0.39
-0.68%
LGND
97.09
-3.81
-3.78%
LPTN
0.28
+0.004
+1.3406%
MBVX
2.52
+0.2
+8.62%
MEIP
1.7
-0.01
-0.58%
MNOV
3.93
-0.02
-0.51%
MRTX
31.69
+0.22
+0.70%
MSTX
0.49
0.00
0.00%
NBIX
47.66
-0.1
-0.21%
NUVA
47.52
+0.14
+0.30%
ONCS
6.6
+0.27
+4.27%
ONVO
3.71
-0.06
-1.59%
OREX
4.93
-0.02
-0.40%
OTIC
22.61
-0.38
-1.65%
QDEL
22.97
+0.02
+0.09%
RCPT
196.27
+6.22
+3.27%
RGLS
10.54
-0.42
-3.83%
RMD
55.3
-1.07
-1.90%
SCIE
0.015
-0.003
-14.773%
SPHS
0.783
-0.002
-0.2676%
SRNE
17.15
-0.47
-2.67%
TROV
9.72
-0.43
-4.24%
VICL
0.685
-0.015
-2.143%
ZGNX
13.96
+0.52
+3.87%
Home » Archive by Category

Xconomy

After Raising $60M, Kura Oncology Renews Work on Shelved Cancer Drug

March 12, 2015 – 4:30 am

[Updated 3/12/15 9:55 am.] Even after the FDA refused to approve the anti-cancer drug tipifarnib in 2005, some experts could see a tantalizing glimmer of potential for patients with acute myeloid…

[[Click headline to continue reading.]]

At Acadia, “Mistakes Were Made,” A Drug Is Delayed & the CEO Is Out

March 11, 2015 – 4:06 pm

On Tuesday, Acadia Pharmaceuticals dropped out of two conferences and its stock price jumped, apparently because investors thought an acquisition was coming. Not quite. Instead San Diego-based Acadia…

[[Click headline to continue reading.]]

At Acadia, “Mistakes Were Made,” A Drug Is Delayed & the CEO Is Out

March 11, 2015 – 4:06 pm

On Tuesday, Acadia Pharmaceuticals dropped out of two conferences and its stock price jumped, apparently because investors thought an acquisition was coming. Not quite. Instead San Diego-based Acadia…

[[Click headline to continue reading.]]

In Move That Spells Relief, Zogenix Sells Painkiller to Pernix

March 10, 2015 – 6:50 pm

Zohydro was supposed to be a new kind of painkiller, but it gave Zogenix CEO Roger Hawley a headache that lasted more than a year. Now perhaps he can rest a little easier. After introducing Zohydro…

[[Click headline to continue reading.]]

In Move That Spells Relief, Zogenix Sells Painkiller to Pernix

March 10, 2015 – 6:50 pm

Zohydro was supposed to be a new kind of painkiller, but it gave Zogenix CEO Roger Hawley a headache that lasted more than a year. Now perhaps he can rest a little easier. After introducing Zohydro…

[[Click headline to continue reading.]]

Companion Diagnostic Specialist AltheaDx Withdraws IPO

March 10, 2015 – 8:20 am

San Diego’s AltheaDx, which offers a series of molecular diagnostic tests that enable doctors to identify the optimal drugs for treating patients, yesterday withdrew its plans for an initial public…

[[Click headline to continue reading.]]

NIH Director Hails “Stunning Case” as Example of Genomic Revolution

March 6, 2015 – 7:37 am

A pregnant mom who got a non-invasive prenatal test because she knew at age 40 that her baby was a higher risk for Down syndrome has become a case study in the potential power of precision medicine….

[[Click headline to continue reading.]]

NIH Director Hails “Stunning Case” as Example of Genomic Revolution

March 6, 2015 – 7:37 am

A pregnant mom who got a non-invasive prenatal test because she knew at age 40 that her baby was a higher risk for Down syndrome has become a case study in the potential power of precision medicine….

[[Click headline to continue reading.]]

West Coast Biotech Roundup: Pharmacyclics, Gates, Ikaria & More

March 5, 2015 – 3:01 pm

[Corrected 3/9/15, 11:46 pm. See below.] What a week for West Coast news, topped off by AbbVie’s surprise $21 billion grab of Pharmacyclics. It’s the ninth-largest biopharma acquisition…

[[Click headline to continue reading.]]

West Coast Biotech Roundup: Pharmacyclics, Gates, Ikaria & More

March 5, 2015 – 3:01 pm

[Corrected 3/9/15, 11:46 pm. See below.] What a week for West Coast news, topped off by AbbVie’s surprise $21 billion grab of Pharmacyclics. It’s the ninth-largest biopharma acquisition…

[[Click headline to continue reading.]]